Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-29
DOI
10.1007/s10549-018-5022-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MCL-1 is a prognostic indicator and drug target in breast cancer
- (2018) Kirsteen J. Campbell et al. Cell Death & Disease
- The Cdk5-Mcl-1 axis promotes mitochondrial dysfunction and neurodegeneration in a model of Alzheimer's disease
- (2017) Kumar Nikhil et al. JOURNAL OF CELL SCIENCE
- Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
- (2017) Delphine Merino et al. Science Translational Medicine
- Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
- (2016) Michelle M. Williams et al. MOLECULAR CANCER RESEARCH
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer
- (2015) C M Goodwin et al. CELL DEATH AND DIFFERENTIATION
- Small molecule Mcl-1 inhibitors for the treatment of cancer
- (2015) Johannes Belmar et al. PHARMACOLOGY & THERAPEUTICS
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker
- (2013) David J. Richard et al. BIOORGANIC & MEDICINAL CHEMISTRY
- An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1
- (2013) Z Zhang et al. BRITISH JOURNAL OF CANCER
- Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction
- (2013) X. Wang et al. GENES & DEVELOPMENT
- A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo
- (2013) F. Abulwerdi et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
- (2013) J. M. Balko et al. Cancer Discovery
- Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency
- (2012) Guo Wei et al. CANCER CELL
- BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions
- (2012) Victoria Del Gaizo Moore et al. CANCER LETTERS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration
- (2012) Rhonda M. Perciavalle et al. NATURE CELL BIOLOGY
- An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
- (2011) S. Al-harbi et al. BLOOD
- Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells
- (2011) A. A. Morales et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
- (2011) Ingrid E. Wertz et al. NATURE
- Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer
- (2011) E P Booy et al. ONCOGENE
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Mcl-1; the molecular regulation of protein function
- (2010) Luke W. Thomas et al. FEBS LETTERS
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy
- (2010) W J Placzek et al. Cell Death & Disease
- BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists
- (2009) K C Goldsmith et al. CELL DEATH AND DIFFERENTIATION
- Spheroid-based drug screen: considerations and practical approach
- (2009) Juergen Friedrich et al. Nature Protocols
- Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell
- (2008) San-Hua Wei et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
- (2008) M Vogler et al. CELL DEATH AND DIFFERENTIATION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started